Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Fibrate (PPAR-α agonist)

Bezafibrate

Brand names: Bezalip Mono, Bezalip

Bezafibrate is a fibrate used as a lipid-modifying agent, principally to lower raised triglycerides and to treat mixed dyslipidaemias.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It activates peroxisome proliferator-activated receptor alpha (PPAR-alpha), enhancing lipoprotein lipase activity and fatty acid oxidation to reduce triglyceride and VLDL levels.

Prescribing in practice

  • The risk of myopathy and rhabdomyolysis is increased, particularly when combined with a statin or in renal impairment; advise patients to report unexplained muscle pain.
  • Dose reduction or avoidance is required in renal impairment, and it is contraindicated in severe renal and hepatic impairment.
  • May potentiate the effect of oral anticoagulants, necessitating closer monitoring of anticoagulation.

Monitoring

Monitor the lipid profile, renal and hepatic function, and check creatine kinase if muscular symptoms develop.

Counselling the patient

  • Report unexplained muscle pain, tenderness or weakness promptly.
  • Continue dietary measures, and inform your prescriber of all other medicines, particularly blood thinners.

Evidence & guidelines

Bezafibrate is an established fibrate for hypertriglyceridaemia, with its use and cautions described in the SPC.

Reference: SmPC Bezalip Mono; ACCORD Lipid trial NEJM 2010; 362:1563-74; NICE CG181; ESC/EAS Dyslipidaemias 2019; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways